Bristol Myers Squibb’s Opdualag recommended by NICE for advanced melanoma
Source: PMLIVE, January 2024
Bristol Myers Squibb’s (BMS) Opdualag (nivolumab-relatlimab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line treatment of advanced melanoma in patients aged 12 years and older.
The incidence of melanoma, a type of skin cancer that develops when pigment-producing cells located in the skin grow uncontrollably, has been rising steadily over the past few decades, with around 16,744 new cases of the disease diagnosed in the UK every year.
Around 10% of patients are diagnosed at stages 3 or 4, and despite melanomas usually being curable when caught early, the disease becomes more difficult to treat as it progresses.